These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
516 related items for PubMed ID: 12606603
1. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL, Williams M, Hancock AA. J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603 [Abstract] [Full Text] [Related]
2. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani YL, Williams M, Hancock AA. Biochem Pharmacol; 2004 Sep 01; 68(5):933-45. PubMed ID: 15294456 [Abstract] [Full Text] [Related]
3. Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. Fox GB, Pan JB, Radek RJ, Lewis AM, Bitner RS, Esbenshade TA, Faghih R, Bennani YL, Williams M, Yao BB, Decker MW, Hancock AA. J Pharmacol Exp Ther; 2003 Jun 01; 305(3):897-908. PubMed ID: 12606600 [Abstract] [Full Text] [Related]
4. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA. J Pharmacol Exp Ther; 2005 Apr 01; 313(1):165-75. PubMed ID: 15608078 [Abstract] [Full Text] [Related]
5. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations. Krueger KM, Witte DG, Ireland-Denny L, Miller TR, Baranowski JL, Buckner S, Milicic I, Esbenshade TA, Hancock AA. J Pharmacol Exp Ther; 2005 Jul 01; 314(1):271-81. PubMed ID: 15821027 [Abstract] [Full Text] [Related]
6. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA. J Pharmacol Exp Ther; 2005 Apr 01; 313(1):176-90. PubMed ID: 15608077 [Abstract] [Full Text] [Related]
7. Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Gbahou F, Vincent L, Humbert-Claude M, Tardivel-Lacombe J, Chabret C, Arrang JM. Br J Pharmacol; 2006 Apr 01; 147(7):744-54. PubMed ID: 16432504 [Abstract] [Full Text] [Related]
10. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. Ligneau X, Lin J, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, Schwartz J. J Pharmacol Exp Ther; 1998 Nov 01; 287(2):658-66. PubMed ID: 9808693 [Abstract] [Full Text] [Related]
11. Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists. Liedtke S, Flau K, Kathmann M, Schlicker E, Stark H, Meier G, Schunack W. Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan 01; 367(1):43-50. PubMed ID: 12616340 [Abstract] [Full Text] [Related]
12. Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand. Witte DG, Yao BB, Miller TR, Carr TL, Cassar S, Sharma R, Faghih R, Surber BW, Esbenshade TA, Hancock AA, Krueger KM. Br J Pharmacol; 2006 Jul 01; 148(5):657-70. PubMed ID: 16715122 [Abstract] [Full Text] [Related]
13. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles. Mor M, Bordi F, Silva C, Rivara S, Crivori P, Plazzi PV, Ballabeni V, Caretta A, Barocelli E, Impicciatore M, Carrupt PA, Testa B. J Med Chem; 1997 Aug 01; 40(16):2571-8. PubMed ID: 9258364 [Abstract] [Full Text] [Related]
14. A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligands. Miller TR, Baranowski JL, Estvander BR, Witte DG, Carr TL, Manelli AM, Krueger KM, Cowart MD, Brioni JD, Esbenshade TA. Assay Drug Dev Technol; 2008 Jun 01; 6(3):339-49. PubMed ID: 18593375 [Abstract] [Full Text] [Related]
15. Histamine H3-receptor-mediated [35S]GTP gamma[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors. Rouleau A, Ligneau X, Tardivel-Lacombe J, Morisset S, Gbahou F, Schwartz JC, Arrang JM. Br J Pharmacol; 2002 Jan 01; 135(2):383-92. PubMed ID: 11815373 [Abstract] [Full Text] [Related]
16. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons. Dai H, Fu Q, Shen Y, Hu W, Zhang Z, Timmerman H, Leurs R, Chen Z. Eur J Pharmacol; 2007 Jun 01; 563(1-3):117-23. PubMed ID: 17350613 [Abstract] [Full Text] [Related]